MedChemExpress LLC reported that Rusfertide was approved as a hepcidin mimetic for polycythemia vera in August 2026.
Public source
Publisher name
Public post
💊#FDA Drug Approvals — August 2026 🔬First-in-class breakthroughs • #Daraxonrasib — a #RAS inhibitor for metastatic pancreatic cancer • #Rusfertide — a hepcidin mimetic…
Company
MedChemExpress LLC
Master of Bioactive Molecules.
- Industry
- Biotechnology Research
- Location
- Monmouth Junction, US
- Company size
- 51–200 employees
About MedChemExpress LLC
MedChemExpress (MCE) is a leading global supplier of life science reagents, dedicated to providing innovative solutions for scientific research and drug development. We offer a comprehensive range of high-quality active molecules, including inhibitors, compound libraries, recombinant proteins, antibodies, and more, positioning itself as a leading global supplier of research chemicals and bioactive compounds. Headquartered in New Jersey, USA, MCE has established multiple R&D, production, and logistics centers worldwide. With a team of seasoned experts, MCE has built an end-to-end service system, encompassing services such as HNMR data analysis, bioactivity evaluation, technical consultation, and after-sales support. Backed by stringent management systems and quality control standards, MCE delivers efficient, precise, and reliable services to over 15,000 research institutions worldwide. Committed to driving innovation in drug discovery, MCE is your trusted long-term partner for scientific exploration and pharmaceutical research. https://linktr.ee/MedChemExpress
See moreLatest activity
Latest activity from MedChemExpress LLC
14 signals
Research & Knowledge
MedChemExpress LLC reported that in a Phase 3 trial, Avexitide reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% vs. placebo in 78 participants, meeting all secondary endpoints.
Research & Knowledge
MedChemExpress LLC published an article tracing the molecular cascade driven by Aβ from production and aggregation to neuronal and synaptic dysfunction.
Research & Knowledge
MedChemExpress LLC published a study finding that mutant KRAS can reshape the tumor microbiome and enrich Bacteroides acidifaciens.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Keros Therapeutics
Keros Therapeutics received approval for rusfertide for polycythemia vera from Protagonist Therapeutics and Takeda.
Legal & Regulatory
HitChem
HitChem received accelerated approval for Iberdomide (CC-220) from BMS, allowing CRBN molecular glue development to continue.
Legal & Regulatory
MPN Research Foundation
MPN Research Foundation reported that the FDA has approved Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera.
Legal & Regulatory
Drug Hunter
Drug Hunter reported that Iberdomide, a CRBN-mediated molecular glue degrader of IKZF1 and IKZF3, received accelerated FDA approval for the treatment of multiple myeloma in August 2026.
Legal & Regulatory
PharmaEssentia